Bausch + Lomb Completes Refinancing of Outstanding Term B Loans

Core Viewpoint - Bausch + Lomb Corporation has successfully closed a credit agreement refinancing, entering into a fourth amendment to its existing credit agreement, which includes a new tranche of term B loans totaling $2,802,125,000 to refinance existing loans due in 2028 and 2031 [1] Group 1: Credit Agreement Details - The new Replacement Term Loans have an amortization rate of 1.00% per annum, with the first installment due on June 30, 2026 [2] - The applicable margin for the Replacement Term Loans is set at 3.75% per annum for loans tied to term SOFR and 2.75% per annum for those tied to the alternate base rate, reflecting a reduction of 0.50% and 0.25% respectively from previous loans [2] - The maturity date for the Replacement Term Loans is January 15, 2031, which aligns with the maturity date of the previously existing loans, effectively extending the maturity of the First Incremental Term Loans from September 29, 2028 [2] Group 2: Company Overview - Bausch + Lomb is a leading global eye health company focused on improving vision and quality of life for individuals worldwide, with a commitment to innovation in eye care [3] - The company has a diverse product portfolio that includes contact lenses, prescription products, over-the-counter options, and surgical devices, aimed at enhancing patient outcomes [3]